Zosano Pharma Corporation News Releases http://ir.zosanopharma.com/ Zosano Pharma Corporation News Releases en Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain http://ir.zosanopharma.com/news-releases/news-release-details/zosano-announces-publication-analysis-acute-treatments-migraine FREMONT, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed trials using newly FDA -recommended Tue, 16 Apr 2019 08:30:00 -0400 Zosano Pharma Corporation News Releases 9021 Zosano Announces Pricing of Public Offering of Common Stock http://ir.zosanopharma.com/news-releases/news-release-details/zosano-announces-pricing-public-offering-common-stock-1 FREMONT, Calif. , April 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million , before deducting underwriting discounts Tue, 09 Apr 2019 09:00:00 -0400 Zosano Pharma Corporation News Releases 9001 Zosano Pharma Announces Proposed Public Offering of Common Stock http://ir.zosanopharma.com/news-releases/news-release-details/zosano-pharma-announces-proposed-public-offering-common-stock FREMONT, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered Mon, 08 Apr 2019 16:01:00 -0400 Zosano Pharma Corporation News Releases 8991 Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results http://ir.zosanopharma.com/news-releases/news-release-details/zosano-pharma-reports-fourth-quarter-and-fiscal-year-2018 FREMONT, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018 , as well as recent business highlights. Thu, 14 Mar 2019 16:05:00 -0400 Zosano Pharma Corporation News Releases 8971 Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference http://ir.zosanopharma.com/news-releases/news-release-details/zosano-pharma-announces-presentation-and-participation-31st FREMONT, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will participate in a panel titled “Drug Delivery” to be held on Monday, Mon, 11 Mar 2019 12:30:00 -0400 Zosano Pharma Corporation News Releases 8961 Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update http://ir.zosanopharma.com/news-releases/news-release-details/zosano-pharma-host-conference-call-fourth-quarter-and-full-year FREMONT, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter Thu, 07 Mar 2019 16:30:00 -0500 Zosano Pharma Corporation News Releases 8951 Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease http://ir.zosanopharma.com/news-releases/news-release-details/zosano-announces-completion-final-milestone-long-term-safety Long-term one-year dosing reaffirmed well-tolerated safety profile Qtrypta showed robust and rapid relief of migraine pain, an effect that was consistent throughout the chronic treatment period NDA submission expected in Q4 2019 for the first intracutaneous delivery system FREMONT, Calif. , Feb. Thu, 21 Feb 2019 06:00:00 -0500 Zosano Pharma Corporation News Releases 8926 Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines http://ir.zosanopharma.com/news-releases/news-release-details/zosano-announces-publication-positive-data-qtryptastm-potential FREMONT, Calif. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a post-hoc analysis of its pivotal Phase 2/3 (ZOTRIP) study in Headache: The Journal Thu, 31 Jan 2019 08:30:00 -0500 Zosano Pharma Corporation News Releases 8916 Zosano Appoints Linda Grais M.D., J.D. to Board of Directors http://ir.zosanopharma.com/news-releases/news-release-details/zosano-appoints-linda-grais-md-jd-board-directors FREMONT, Calif. , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais , M.D., J.D. to its board of directors. Dr. Wed, 16 Jan 2019 08:30:00 -0500 Zosano Pharma Corporation News Releases 8896 Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta™ for M207 http://ir.zosanopharma.com/news-releases/news-release-details/zosano-receives-conditional-fda-acceptance-proposed-brand-name FREMONT, Calif. , Dec. 12, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation  (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has conditionally accepted the proposed brand name Qtrypta™ for Wed, 12 Dec 2018 08:30:00 -0500 Zosano Pharma Corporation News Releases 8881